KR102111157B1 - 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 - Google Patents

피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 Download PDF

Info

Publication number
KR102111157B1
KR102111157B1 KR1020187012966A KR20187012966A KR102111157B1 KR 102111157 B1 KR102111157 B1 KR 102111157B1 KR 1020187012966 A KR1020187012966 A KR 1020187012966A KR 20187012966 A KR20187012966 A KR 20187012966A KR 102111157 B1 KR102111157 B1 KR 102111157B1
Authority
KR
South Korea
Prior art keywords
castor oil
salt
pharmaceutical composition
pyridin
polyoxyethylene castor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187012966A
Other languages
English (en)
Korean (ko)
Other versions
KR20180050770A (ko
Inventor
요코 엔도
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20180050770A publication Critical patent/KR20180050770A/ko
Application granted granted Critical
Publication of KR102111157B1 publication Critical patent/KR102111157B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187012966A 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 Active KR102111157B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2014-002809 2014-01-10
JP2014002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167016400A Division KR101858373B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013304A Division KR102230683B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Publications (2)

Publication Number Publication Date
KR20180050770A KR20180050770A (ko) 2018-05-15
KR102111157B1 true KR102111157B1 (ko) 2020-05-14

Family

ID=53523959

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020187012966A Active KR102111157B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020227036348A Active KR102675685B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020247019428A Active KR102984133B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020207013304A Active KR102230683B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020167016400A Active KR101858373B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020217007751A Active KR102458180B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020227036348A Active KR102675685B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020247019428A Active KR102984133B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020207013304A Active KR102230683B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020167016400A Active KR101858373B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR1020217007751A Active KR102458180B1 (ko) 2014-01-10 2015-01-08 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Country Status (19)

Country Link
US (3) US20160317512A1 (cg-RX-API-DMAC7.html)
EP (2) EP3093021B1 (cg-RX-API-DMAC7.html)
JP (5) JP6012775B2 (cg-RX-API-DMAC7.html)
KR (6) KR102111157B1 (cg-RX-API-DMAC7.html)
CN (2) CN110251516B (cg-RX-API-DMAC7.html)
AU (1) AU2015205268B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016015911B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934612C (cg-RX-API-DMAC7.html)
EA (1) EA031723B1 (cg-RX-API-DMAC7.html)
ES (2) ES2953346T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20186916B (cg-RX-API-DMAC7.html)
IL (1) IL246654B (cg-RX-API-DMAC7.html)
MX (1) MX2016009058A (cg-RX-API-DMAC7.html)
MY (1) MY166210A (cg-RX-API-DMAC7.html)
PH (1) PH12016501327A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201605532YA (cg-RX-API-DMAC7.html)
TW (1) TWI612960B (cg-RX-API-DMAC7.html)
UA (1) UA121744C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015105134A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200053651A (ko) * 2014-01-10 2020-05-18 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
TWI794140B (zh) 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3689349A4 (en) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
US11666563B2 (en) * 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CN114761022B (zh) * 2019-11-29 2024-02-13 千寿制药株式会社 药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
WO2009113600A1 (ja) 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
WO2010113957A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 緑内障の治療又は予防のための医薬組成物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP5460996B2 (ja) 2007-10-19 2014-04-02 大正製薬株式会社 眼科用剤
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
TW201309343A (zh) 2011-02-10 2013-03-01 參天製藥股份有限公司 經改善親水性藥物之藥物移行性之水性組成物
CN103596572A (zh) 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
TW201340960A (zh) 2012-02-27 2013-10-16 Rohto Pharma 眼科用組成物套組
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
CN104428911B (zh) 2012-07-09 2018-08-24 夏普株式会社 发光装置以及照明装置
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
KR102074020B1 (ko) 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
KR102111157B1 (ko) 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
EP3689349A4 (en) 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
WO2009113600A1 (ja) 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
WO2010113957A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 緑内障の治療又は予防のための医薬組成物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200053651A (ko) * 2014-01-10 2020-05-18 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR102230683B1 (ko) * 2014-01-10 2021-03-19 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR20210032547A (ko) * 2014-01-10 2021-03-24 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR102458180B1 (ko) * 2014-01-10 2022-10-21 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR20220146691A (ko) * 2014-01-10 2022-11-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR102675685B1 (ko) * 2014-01-10 2024-06-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
KR102984133B1 (ko) * 2014-01-10 2026-06-29 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Also Published As

Publication number Publication date
KR102458180B1 (ko) 2022-10-21
GEP20186916B (en) 2018-11-12
US20230372316A1 (en) 2023-11-23
KR102230683B1 (ko) 2021-03-19
EA201691139A1 (ru) 2017-02-28
JP2019034973A (ja) 2019-03-07
US20160317512A1 (en) 2016-11-03
EP3888654A1 (en) 2021-10-06
IL246654A0 (en) 2016-08-31
JP7546027B2 (ja) 2024-09-05
WO2015105134A1 (ja) 2015-07-16
JP2022189964A (ja) 2022-12-22
PH12016501327B1 (en) 2017-02-06
BR112016015911A2 (cg-RX-API-DMAC7.html) 2017-08-08
UA121744C2 (uk) 2020-07-27
JP2021011508A (ja) 2021-02-04
KR20160100977A (ko) 2016-08-24
EP3093021B1 (en) 2021-06-02
MX2016009058A (es) 2016-09-09
HK1224191A1 (zh) 2017-08-18
KR102675685B1 (ko) 2024-06-14
CN110251516A (zh) 2019-09-20
CA2934612A1 (en) 2015-07-16
CN105828817A (zh) 2016-08-03
BR112016015911B1 (pt) 2022-04-05
KR20180050770A (ko) 2018-05-15
JP2017031177A (ja) 2017-02-09
SG11201605532YA (en) 2016-08-30
EP3093021A1 (en) 2016-11-16
JP6449205B2 (ja) 2019-01-09
KR20210032547A (ko) 2021-03-24
KR20220146691A (ko) 2022-11-01
JP6012775B2 (ja) 2016-10-25
ES2953346T3 (es) 2023-11-10
IL246654B (en) 2020-05-31
JP7170020B2 (ja) 2022-11-11
JP6793172B2 (ja) 2020-12-02
KR101858373B1 (ko) 2018-05-15
KR102984133B1 (ko) 2026-06-29
TW201611833A (en) 2016-04-01
US20200113880A1 (en) 2020-04-16
JP2015147762A (ja) 2015-08-20
KR20240096869A (ko) 2024-06-26
US12678429B2 (en) 2026-07-14
EA031723B1 (ru) 2019-02-28
MY166210A (en) 2018-06-22
CN105828817B (zh) 2019-07-05
TWI612960B (zh) 2018-02-01
AU2015205268B2 (en) 2019-03-14
NZ721530A (en) 2021-03-26
CN110251516B (zh) 2022-05-03
EP3093021A4 (en) 2017-07-26
ES2874547T3 (es) 2021-11-05
EP3888654B1 (en) 2023-06-14
KR20200053651A (ko) 2020-05-18
AU2015205268A1 (en) 2016-07-14
GEAP201814216A (en) 2018-07-25
PH12016501327A1 (en) 2017-02-06
CA2934612C (en) 2021-09-07

Similar Documents

Publication Publication Date Title
JP7546027B2 (ja) ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
KR102281620B1 (ko) 피리딜아미노아세트산 화합물을 함유하는 의약 조성물
NZ721530B2 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1224191B (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1227322A1 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1227322B (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180504

Application number text: 1020167016400

Filing date: 20160620

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191022

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191028

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200207

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200508

Application number text: 1020167016400

Filing date: 20160620

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200511

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230329

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240402

Start annual number: 5

End annual number: 5